Reagila kaps. tver. 6 mg No. 28

Reagil is applied to treatment of schizophrenia at adult patients.

Structure

Active ingredient: kariprazin.

1 capsule supports a kariprazin of 6 mg;

Contraindication

Hypersensitivity to active ingredient or to any of excipients.

Simultaneous use of powerful or moderate CYP3A4 inhibitor.

Route of administration

Recommended initial dose of a kariprazin makes 1.5 mg once a day. Subsequently a dose in case of need it is possible to increase 1.5 mg to the maximum 6 mg/days slowly. The lowest effective dose has to be supported according to clinical assessment of the doctor. In long elimination half-life of a kariprazin and its active metabolites of change in a dosage will not be displayed completely in plasma within several weeks. Patients it is necessary to observe concerning emergence of side reactions and the response to treatment within several weeks after the beginning of reception of a kariprazin and after each change of a dose.

Use of the medicament Reagila is not recommended to

Feature of use

during pregnancy and also to women of childbearing age who do not use effective contraception. After the treatment termination karipraziny because of a slow conclusion of active components the methods of contraception should be applied within not less than 10 weeks.

to

Children

Safety and efficiency of use of a kariprazin for children (aged up to 18 years) it is not established. There are no data.

Drivers

Kariprazin has weak or moderate influence on ability of patients to run motor transport and to work with mechanisms. Patients need to be warned against work with dangerous mechanisms, including motor transport until they are completely sure that Reagila medicine has on them no negative impact.

Overdose

It was reported about accidental acute overdose (48 mg/days) at one patient. At this patient appeared ortostaz and sedation. A condition of the patient it was completely restored on the same day.

Side effects

Side reactions about which it was most often reported at use of a kariprazin in the range of doses (1.5-6 mg) were an akathisia (19%) and parkinsonism (17.5%). The majority of reactions were easy or moderate severity.

on the systems of bodies.

Interaction

Metabolism of a kariprazin and its main active metabolites, the dezmetil-kariprazina (DCAR) and a didezmetilu-kariprazin (DDCAR), is mainly mediated by CYP3A4 with the minimum influence of CYP2D6.

Ketokonazol, strong CYP3A4 inhibitor, leads to increase in maintenance of the general kariprazin (sum of a kariprazin and its active metabolites) in plasma twice during short (4 days) the accompanying use if the connected components are considered untied or untied +.

In long elimination half-life of active components of a kariprazin the further increase in maintenance of the general kariprazin in plasma can be expected at longer combined reception. Therefore the combined reception of a kariprazin with powerful or moderate CYP3A4 inhibitors (for example, botseprevir, klaritromitsin, kobitsistat, indinavir, itrakonazol, ketokonazol, nefazodon, nelfinavir, pozakonazol, ritonavir, sakvinavir, telaprevir, telitromitsin, vorikonazol, diltiazem, erythromycin, flukonazol, verapamil) is contraindicated. It is necessary to avoid consumption of grapefruit juice.

to Store

in original packing at a temperature not above 25 °C. To store out of children's reach.

Expiration date - 5 years.